DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) is a clinical and
commercial stage biopharmaceutical company focused on the development of novel
therapeutics for the treatment of cancer. The company’s leading product
candidate, VAL-083, is a first-in-class small molecule chemotherapeutic that is
currently undergoing clinical trials in the United States as a potential treatment
for refractory glioblastoma multiforme (GBM), the most common and aggressive
form of brain cancer. Previously, the drug candidate has been the subject of
extensive research by the U.S. National Cancer Institute, and it is currently
approved for the treatment of chronic myelogenous leukemia (CML) and lung
cancer in China.
In June, DelMar presented an update on its phase I/II
clinical trial of VAL-083, and the initial results provide a promising outlook
for the company. Despite having failed prior treatment with standard front-line
options and having a growing GBM tumor at the time of enrollment in the DelMar
clinical trial, 59 percent of patients treated with VAL-083 recorded better
than average survival rates. With proper dosing, an improved median overall
survival of about nine months was achieved, which marked a meaningful survival
benefit over currently available treatment options.
“The overall survival demonstrated at the higher doses in
our clinical trial with only two cycles of treatment is clinically meaningful
in comparison to published outcomes in this patient population,” Jeffrey Bacha,
president and chief executive officer of DelMar, stated in a news release. “We
consider these results to be positive and supportive of the further development
of VAL-083 as a potential new therapy for GBM patients who have failed other
available treatments.”
In the months to come, DelMar will initiate activities to
prepare for advancement to registration-directed phase II/III clinical trials
of VAL-083. As the company approaches the eventual commercialization of its
drug candidate, early results indicate that it could have the potential to
replace temozolomide as the standard of care in newly-diagnosed GBM patients
whose tumors express features correlated with resistance to standard
chemotherapy.
The potential market for DelMar’s drug candidate upon
commercialization with the United States is expansive. According to the
American Brain Tumor Association, nearly 700,000 people in the U.S. are
currently living with a brain tumor, and nearly 70,000 new cases are diagnosed
each year. Among these cases, approximately 17 percent are related to GBM. By
providing an improved therapeutic option to temozolomide-resistant GBM, the
company is in a strong position to promote sustainable growth moving forward.
For prospective shareholders, DelMar’s continued progress
toward the domestic commercialization of VAL-083 makes the company an
intriguing investment option in the coming months.
For more information, visit www.delmarpharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment